• Gerard O Oghlakian, Ilke Sipahi, and James C Fang.
• Division of Cardiovascular Medicine, University Hospitals of Cleveland, Case Medical Center, Cleveland, OH, USA. gerard.oghlakian@UHhospitals.org
• Mayo Clin. Proc. 2011 Jun 1; 86 (6): 531539531-9.

AbstractHeart failure with preserved ejection fraction (HF-PEF) is the clinical syndrome of heart failure associated with normal or near-normal systolic function. Because inhibition of the adrenergic and renin-angiotensin-aldosterone systems has been so effective in the treatment of systolic heart failure, these same therapies have been the subject of recent clinical trials of HF-PEF. In this review, we examine the current evidence about treatment of HF-PEF, with particular emphasis on reviewing the literature for large-scale randomized clinical studies. The lack of significant benefit with neurohormonal antagonism in HF-PEF suggests that this condition might not involve neurohormonal activation as a critical pathophysiologic mechanism. Perhaps heart failure as we traditionally think of it is the wrong paradigm to pursue as we try to understand this condition of volume overload known as HF-PEF.

46 keywords...

hide…